
MUDr. Lenka Gescheidtová, Ph.D.
odborná asistentka – Biochemický ústav
kancelář: bud. C03/335
Kamenice 753/5
625 00 Brno
telefon: | 549 49 7641 |
---|---|
e‑mail: | lenka.gescheidtova@med.muni.cz |
sociální a akademické sítě: |
---|
Počet publikací: 13
2024
-
Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer
BMC Cancer, rok: 2024, ročník: 24, vydání: December, DOI
2023
-
The effectiveness of three mobile-based psychological interventions in reducing psychological distress and preventing stress-related changes in the psycho-neuro-endocrine-immune network in breast cancer survivors: Study protocol for a randomised controlled trial
Internet Interventions, rok: 2023, ročník: 32, vydání: April 2023, DOI
2021
-
Interpretive discrepancies caused by target values inter-batch variations in chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG by MAGLUMI
Journal of Medical Virology, rok: 2021, ročník: 93, vydání: 3, DOI
-
Strict Adherence to Anti-Epidemic Measures PreventsICU Staff from SARS-Cov2 Infection
Biomedical and Pharmacology Journal, rok: 2021, ročník: 14, vydání: 4, DOI
2020
2019
-
Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
Frontiers in Oncology, rok: 2019, ročník: 9, vydání: NOV 14 2019, DOI
-
Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome
Frontiers in Oncology, rok: 2019, ročník: 9, vydání: OCT 25 2019, DOI
-
Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy
Rok: 2019, druh: Konferenční abstrakty
-
Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine
Rok: 2019, druh: Konferenční abstrakty
-
Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.
International Immunopharmacology, rok: 2019, ročník: 74:105728, DOI